Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

SIMPLE SUMMARY: Osimertinib, a third-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has shown marked clinical benefit for non-small cell lung cancer (NSCLC) patients with EGFR activating mutations. However, resistance to osimertinib inevitably develo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: La Monica, Silvia, Fumarola, Claudia, Cretella, Daniele, Bonelli, Mara, Minari, Roberta, Cavazzoni, Andrea, Digiacomo, Graziana, Galetti, Maricla, Volta, Francesco, Mancini, Maicol, Petronini, Pier Giorgio, Tiseo, Marcello, Alfieri, Roberta
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7792603/
https://ncbi.nlm.nih.gov/pubmed/33374971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13010006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados